134 related articles for article (PubMed ID: 37988841)
1. Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - Implications in treatment outcomes.
Núñez KG; Sandow T; Gimenez J; Hibino M; Fort D; Cohen AJ; Thevenot PT
Eur J Cancer; 2024 Jan; 196():113442. PubMed ID: 37988841
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
3. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
4. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
[TBL] [Abstract][Full Text] [Related]
6. PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival.
Núñez KG; Sandow T; Fort D; Hibino M; Wright P; Cohen AJ; Thevenot PT
Cancer Immunol Immunother; 2022 Jun; 71(6):1453-1465. PubMed ID: 34689234
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
[TBL] [Abstract][Full Text] [Related]
8. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
9. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
[TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Salem R; Johnson GE; Kim E; Riaz A; Bishay V; Boucher E; Fowers K; Lewandowski R; Padia SA
Hepatology; 2021 Nov; 74(5):2342-2352. PubMed ID: 33739462
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
[TBL] [Abstract][Full Text] [Related]
13. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.
Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H
J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Zahran AM; Hetta HF; Rayan A; Eldin AS; Hassan EA; Fakhry H; Soliman A; El-Badawy O
Cancer Immunol Immunother; 2020 Jul; 69(7):1253-1263. PubMed ID: 32170378
[TBL] [Abstract][Full Text] [Related]
15. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
16. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
[No Abstract] [Full Text] [Related]
17. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Lewis S; Cedillo MA; Lee KM; Bane O; Hectors S; Ma W; Wang P; Stocker D; Morris DV; Pinato D; Sung M; Marron T; Schwartz M; Taouli B
Abdom Radiol (NY); 2022 Mar; 47(3):969-980. PubMed ID: 34964909
[TBL] [Abstract][Full Text] [Related]
18. Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.
Wehrenberg-Klee E; Gandhi RT; Ganguli S
Tech Vasc Interv Radiol; 2019 Jun; 22(2):70-73. PubMed ID: 31079713
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.
Memon K; Kulik L; Lewandowski RJ; Mulcahy MF; Benson AB; Ganger D; Riaz A; Gupta R; Vouche M; Gates VL; Miller FH; Omary RA; Salem R
J Hepatol; 2013 Jan; 58(1):73-80. PubMed ID: 23000237
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activity assessment by
Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
